Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept c...

Celý popis

Podrobná bibliografie

Vydáno v:	EBioMedicine Ročník 66; s. 103310
Hlavní autoři:	Talaat, Kawsar R., Alaimo, Cristina, Martin, Patricia, Bourgeois, A. Louis, Dreyer, Anita M., Kaminski, Robert W., Porter, Chad K., Chakraborty, Subhra, Clarkson, Kristen A., Brubaker, Jessica, Elwood, Daniel, Frölich, Rahel, DeNearing, Barbara, Weerts, Hailey, Feijoo, Brittany L., Halpern, Jane, Sack, David, Riddle, Mark S., Fonck, Veronica Gambillara
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 01.04.2021 Elsevier
Témata:	Advanced Basic Science Bioconjugate vaccine Controlled human challenge study Internal Medicine Research Paper Shigella Shigella flexneri 2a Vaccine Controlled human challenge study Vaccine Shigella flexneri 2a Bioconjugate vaccine Shigella
ISSN:	2352-3964, 2352-3964
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!